Oral spironolactone improves acne vulgaris and reduces sebum excretion. 1984

A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise

In a consecutive series of thirty-six male and female patients referred with severe acne, the effect of 3 months' treatment with placebo or spironolactone (50-200 mg daily) on sebum excretion and clinical and endocrine status was evaluated double-blind. Twenty-six patients completed the study. Abnormal free androgen indices were found in 27% of the original nineteen female subjects. Spironolactone reduced sebum excretion in all female subjects, but there was no correlation between sebum response and androgen status. The clinical response was dose-dependent, with maximum subjective and objective benefit when spironolactone doses of 150-200 mg were used.

UI MeSH Term Description Entries
D008297 Male Males
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000152 Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors. Acne
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
March 1970, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
August 1971, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
November 1970, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
August 2022, Journal of cosmetic dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
January 2021, Dermatologic therapy,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
August 1986, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
August 1971, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
July 1971, The British journal of dermatology,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
January 2006, Aesthetic plastic surgery,
A Goodfellow, and J Alaghband-Zadeh, and G Carter, and J J Cream, and S Holland, and J Scully, and P Wise
December 1965, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!